期刊文献+

IL-32在病理性瘢痕基因治疗中的研究进展

Research Progress of IL-32 Gene Therapy in Pathological Scars
下载PDF
导出
摘要 白细胞介素(IL)32是新近发现的炎性细胞因子,能诱生细胞因子的产生,且在调节细胞增殖与凋亡过程中有重要作用。瘢痕组织中成纤维细胞IL-32基因的蛋白表达水平明显低下,提示在瘢痕成纤维细胞中存在IL-32基因的缺失。随着基因治疗技术的日益成熟,以IL-32为目的基因导入到瘢痕成纤维细胞中来调控过度增生的成纤维细胞及减少胶原等大量细胞外基质的过度产生和沉积。现就IL-32的生物学特性及在病理性瘢痕中的作用及应用前景等进行综述,以期为以后的实验及临床作铺垫。 Interleukin(IL)32 is a newly discovered inflammatory cytokine which can induce the production of cytokine playing an important role in regulation of cell proliferation and apoptosis.It is the significantly lower expression levels of IL-32 gene that prompt IL-32 gene deletion in scar fibroblasts.With increasingly sophisticated technology in gene therapy,we import IL-32 as the target gene into scar fibroblasts to regulate cell proliferation and apoptosis and reduce the large number of extracellular matrix collagen overproduction and deposition.Here is to make a review on the biological characteristics of IL-32 and the function and application prospects in pathological scars,for further lab and clinical research.
出处 《医学综述》 2012年第9期1284-1286,共3页 Medical Recapitulate
基金 2009年广东省自然科学基金(9151008002000010)
关键词 白细胞介素32 病理性瘢痕 成纤维细胞 基因治疗 Interleukin-32 Hypertrophic scar Fibroblast Gene therapy
  • 相关文献

参考文献23

  • 1Oh JH, Cho MC, Kim JH, et al. IL-32γinhibits cancer cell growth through inactivation of NF-κB and STAT3 signals [ J]. Oneogene, 2011,30(30) :3345-3359.
  • 2Kim SH, Han SY, Azam T, et al. Interleukin-32 : a cytokine and in- ducer of TNFalpha[ J]. Immunity ,2005,22( 1 ) : 131-142.
  • 3李奇凤,袁俐,张向晖.白介素-32及其与结核病的关系[J].生命的化学,2007,27(4):337-339. 被引量:4
  • 4Chol J, Bae S, Ryoo S, et al. Paradoxical effects of constitutive hu- man IL-32γ, in transgenic mice during experimental colitis [ J 1. Proc Natl Acad Sci U S A,2010,107(49) :21082-21086.
  • 5Xing H, Mc Donagh PD, Bienkowska J, et al. Causal modeling u- sing network ensemble simulations of genetic and gene expression data predicts genes involved in rheumatoid arthritis[ J]. PLoS Com- put Bio1,2011,7 (3) : el001105.
  • 6Coda C, Kanaji T, Kanaji S, et al. Involvement of IL-32 inactiva- tion-induced cell death in T cells[J]. Int Immunol,2006,18 (2) : 233-240.
  • 7Alsaleh G, Sparsa L, Chatelus E, et al. Innate immunity triggers IL- 32 expression by fibroblast-like synoviocytes in rheumatoid arthritis [ J ]. Arthritis Res Ther,2010,12 (4) : R135.
  • 8Felaco P, Castellani ML, De Lutiis MA,et al. IL-32 :a newly-discov- ered proinflammatory cytokine [ J ]. J Biol Regul Homeost Agents, 2009,23 (3) : 141-147.
  • 9Heinhuis B, Koenders MI, van de Loo FA, et al. Inflammation-de- pendent secretion and splicing of IL-32γ in rheumatoid arthritis [J]. Proc Natl Acad Sci U S A,2011,108(12) :4962-4967.
  • 10王春梅,百束比古,中泽南堂.增生性瘢痕和瘢痕疙瘩p53基因多态性的分析[J].中华整形外科杂志,2005,21(1):32-35. 被引量:26

二级参考文献51

  • 1Alhady SMA, Sivanan TK. Keloids in various races: a review of 175 cases. Plast Reconstr Surg, 1969,44:564-566.
  • 2Ramakrishnan KM, Thomas KP, Sundararajan CR. Study of 1000patients with keloids in South India. Plast Reconstr Surg, 1974,53:276-280.
  • 3Levine AJ. p53, the cellular gatekeeper for growth and division. Cell,1997,88:323-331.
  • 4Balmain A, Harris CC. Carcinogenesis in mouse and human cells:parallels and paradoxes. Carcinogenesis, 2000,21: 371-377.
  • 5Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science, 1993,262:1980-1982.
  • 6Beckman G, Birgander R, Sjalander A, et al. Is p53 polymorphism maintained by natural selection? Hum Hered, 1994,44: 266-270.
  • 7Yu MW, Yang SY, Chiu YH, et al. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers.Hepatology, 1999,29: 697-702.
  • 8Oura T, Sugihara H, Yoshida T. The definition and clinical classification of keloids and hypertrophic scars. Japan J Plast Reconstr Surg, 1993,36: 265-274.
  • 9Sugano K, Nakashima Y, Yamaguchi K, et al. Sensitive detection of loss of heterozygosity in the Tp53 gene in pancreatic adenocarcinoma by fluorescence-based single-strand conformation polymorphism analysis using blunt-end DNA fragments. Genes Chromosomes Cancer, 1996,15:157-164.
  • 10Murata M, Tagawa M, Kimura M, et al. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis, 1996,17: 261-264.

共引文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部